REV7/REV3L-IN-1 do-PEG5-acid 5BrH/c2*1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27

5BrH/c2*1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27

is a labeled Glycogen Synthase Kinase 3β (GSK-3β) inhibitor

NSC781406 demonstrates cytotoxic activities against leukemia

SCLC NCI-H146 cells

05-5 μM) reverses Aβ-induced axonal degeneration in cultured neurons

REV7/REV3L-IN-1 do-PEG5-acid 5BrH/c2*1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27REV7 REV3L IN 1 is a REV7 REV3L interaction inhibitor with an IC50 of 78 M, which directly binds to REV7 in nuclear magnetic resonance analyses, and inhibits the reactivation of a reporter plasmid containing an interstrand crosslink (ICL) in between the promoter and reporter regions. Product information CAS Number: 1979192 13 6 Molecular Weight: 371. 45 Formula: C19H21N3O3S Chemical Name: 3 [(1 acetylpiperidin 4 yl)methyl] 5 (5 methylfuran 2 yl) 3H,4H